Continuous glucose monitor

Diabetes app Glucose Buddy now supports Dexcom CGM devices

Retrieved on: 
Tuesday, February 12, 2019

PALO ALTO, Calif., Feb. 12, 2019 /PRNewswire/ -- Azumio , the company behind leading diabetes app Glucose Buddy is working together with Dexcom to bring continuous glucose monitoring to its users.

Key Points: 
  • PALO ALTO, Calif., Feb. 12, 2019 /PRNewswire/ -- Azumio , the company behind leading diabetes app Glucose Buddy is working together with Dexcom to bring continuous glucose monitoring to its users.
  • This technology, developed by Dexcom and available by prescription in the US and other countries, greatly simplifies blood glucose monitoring, especially for people with Type 1 diabetes.
  • Now, Glucose Buddy users with Dexcom G6 devices will be better equipped to manage their diabetes and understand how their food choices, exercise, sleep and other factors impact their glucose level.
  • Along with Dexcom's continuous blood sugar monitoring integration, Azumio also introduces a new AI based feature inside the Glucose Buddy app, Meal IQ.

Senseonics Announces Extension of Distribution Agreement with Roche Diabetes Care

Retrieved on: 
Sunday, February 3, 2019

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced an extension of its distribution agreement with Roche Diabetes Care.

Key Points: 
  • Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced an extension of its distribution agreement with Roche Diabetes Care.
  • Under terms of the extended agreement, Roche will continue its role as Senseonics exclusive distributor in Europe, the Middle East and Africa, excluding Scandinavia and Israel.
  • We are excited about the ongoing and incremental commitment from Roche, both from a geographic expansion and volume perspective.
  • These forward-looking statements should not be relied upon as representing Senseonics views as of any date subsequent to the date hereof.

Senseonics Eversense CGM Sensor Receives Indication for MRI

Retrieved on: 
Thursday, January 31, 2019

Now patients using Eversense CGM do not need to worry about an emergency MRI or delay getting a scheduled MRI based on their glucose sensor.

Key Points: 
  • Now patients using Eversense CGM do not need to worry about an emergency MRI or delay getting a scheduled MRI based on their glucose sensor.
  • Now patients can safety get an MRI* while still wearing the Eversense Sensor the only CGM sensor that is indicated by the FDA for this use.
  • Senseonics' CGM systems, Eversense and Eversense XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor.
  • Share this information with your imaging facility while scheduling your MRI so that they can determine if the MRI equipment in their facility is safe to use with the Eversense Sensor.

Senseonics Appoints Jon D. Isaacson as Chief Financial Officer

Retrieved on: 
Monday, January 7, 2019

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the appointment of Jon D. Isaacson as the companys Chief Financial Officer, effective immediately.

Key Points: 
  • Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the appointment of Jon D. Isaacson as the companys Chief Financial Officer, effective immediately.
  • He brings a strong background of financial and operational success to the company at a pivotal time as we enter our next phase launching the Eversense system in the U.S., said Tim Goodnow, President and Chief Executive Officer.
  • Most recently he served as Chief Financial Officer of Edelman Financial Services where he was responsible for financial planning and analysis, tax, treasury and corporate development.
  • These forward-looking statements should not be relied upon as representing Senseonics views as of any date subsequent to the date hereof.

Ascensia Diabetes Care Announces Global Partnership With POCTech to Distribute and Co-develop Continuous Glucose Monitoring Systems

Retrieved on: 
Monday, January 7, 2019

Ascensia Diabetes Care today announced it has entered into a global alliance with Zhejiang POCTech, Co., Ltd (POCTech), a developer and manufacturer of continuous glucose monitoring (CGM) systems.

Key Points: 
  • Ascensia Diabetes Care today announced it has entered into a global alliance with Zhejiang POCTech, Co., Ltd (POCTech), a developer and manufacturer of continuous glucose monitoring (CGM) systems.
  • "We are committed to expanding our business beyond blood glucose monitoring and we see continuous glucose monitoring as a critical component of diabetes care.
  • Ascensia has a long heritage in diabetes care and this co-development agreement will leverage its in-house expertise and capabilities in developing and commercializing diabetes technologies.
  • For further information, please visit the Ascensia Diabetes Care website at: http://www.ascensia.com
    Ascensia and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings.

Ascensia Diabetes Care Announces Global Partnership With POCTech to Distribute and Co-develop Continuous Glucose Monitoring Systems

Retrieved on: 
Monday, January 7, 2019

Ascensia Diabetes Care today announced it has entered into a global alliance with Zhejiang POCTech, Co., Ltd (POCTech), a developer and manufacturer of continuous glucose monitoring (CGM) systems.

Key Points: 
  • Ascensia Diabetes Care today announced it has entered into a global alliance with Zhejiang POCTech, Co., Ltd (POCTech), a developer and manufacturer of continuous glucose monitoring (CGM) systems.
  • "We are committed to expanding our business beyond blood glucose monitoring and we see continuous glucose monitoring as a critical component of diabetes care.
  • Ascensia has a long heritage in diabetes care and this co-development agreement will leverage its in-house expertise and capabilities in developing and commercializing diabetes technologies.
  • For further information, please visit the Ascensia Diabetes Care website at: http://www.ascensia.com
    Ascensia and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings.

Diabeloop at CES in Las Vegas to Present Its Groundbreaking Automated Insulin Delivery System for Type 1 Diabetes

Retrieved on: 
Monday, December 17, 2018

The solution developed by Diabeloop is an integrated closed-loop insulin delivery system made up of three devices: a continuous glucose monitor (CGM), a patch insulin pump and a handset terminal hosting the algorithms developed by Diabeloop and acting as a user interface with the system.

Key Points: 
  • The solution developed by Diabeloop is an integrated closed-loop insulin delivery system made up of three devices: a continuous glucose monitor (CGM), a patch insulin pump and a handset terminal hosting the algorithms developed by Diabeloop and acting as a user interface with the system.
  • These algorithms predict blood sugar levels and instruct the pump to automatically deliver insulin doses.
  • At CES 2019, Diabeloop will present its innovative R&D-intensive system developed with and for children and their loved ones.
  • Diabeloop and CEA-Leti work together at a shared research laboratory to speed up the development of the system.

Opportunity Analysis on the Global Continuous Glucose Monitoring (CGM) Systems/Devices Market to 2024 - Increasing Number of Patients Opting for Simplified CGM Devices

Retrieved on: 
Thursday, November 15, 2018

The global continuous glucose monitoring (CGM) devices market size is expected to reach USD 1.01 billion by 2024.

Key Points: 
  • The global continuous glucose monitoring (CGM) devices market size is expected to reach USD 1.01 billion by 2024.
  • Growing cases of diabetes and introduction of novel and advanced diabetes care devices are the major factors driving the market growth.
  • Thus, an increasing number of diabetic patients are using these devices to manage and treat diabetes, which, in turn, is accelerating market growth.
  • Growing cases of diabetes is anticipated to propel market growth, with increasing number of patients opting for simplified CGM devices.

Global Continuous Glucose Monitoring Devices (CGM) Market is projected to display a high growth represented by a CAGR of 21.25% during 2018 - 2023

Retrieved on: 
Tuesday, November 6, 2018

The report assesses the Continuous Glucose Monitoring Device Market for the period 2013-2017 and for the forecast period 2018-2023.

Key Points: 
  • The report assesses the Continuous Glucose Monitoring Device Market for the period 2013-2017 and for the forecast period 2018-2023.
  • According to Azoth Analytics research report "Global Continuous Glucose Monitoring Devices (CGM) Market: Analysis By Component (Transmitter & Receiver, Sensor, Integrated Insulin Pump), By Demographics, End-User, By Region, By Country (2018 Edition): Forecast to 2023", the global market is projected to display a high growth represented by a CAGR of 21.25% during 2018 2023.
  • Amongst the regions, North America accounts for the largest regional share in the global continuous glucose monitoring devices market in 2018.
  • Global Continuous Glucose Monitoring Devices Market (Actual Period: 2013-2017, Forecast Period: 2018-2023)
    Continuous Glucose Monitoring Devices Market Size, Growth, Forecast
    By Component Transmitter & receiver, Sensor, Integrated Insulin Pump
    Regional Markets North America, Europe, Asia-Pacific and Rest of the World (Actual Period: 2013-2017, Forecast Period: 2018-2023)
    Continuous Glucose Monitoring Devices Market Size, Growth, Forecast
    By Component Transmitter & receiver, Sensor, Integrated Insulin Pump
    Continuous Glucose Monitoring Devices Market Size, Growth, Forecast
    By Component Transmitter & receiver, Sensor, Integrated Insulin Pump

Global Continuous Glucose Monitoring Devices (CGM) Market to 2023 - Market is Projected to Grow a CAGR of 21.25%

Retrieved on: 
Monday, November 5, 2018

The global market is projected to display a high growth represented by a CAGR of 21.25% during 2018 - 2023.

Key Points: 
  • The global market is projected to display a high growth represented by a CAGR of 21.25% during 2018 - 2023.
  • Amongst the regions, North America accounts for the largest regional share in the global continuous glucose monitoring devices market in 2018.
  • Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global continuous glucose monitoring devices market.
  • Global Continuous Glucose Monitoring Devices Market (Actual Period: 2013-2017, Forecast Period: 2018-2023)
    Continuous Glucose Monitoring Devices Market - Size, Growth, Forecast
    By Component - Transmitter & receiver, Sensor, Integrated Insulin Pump
    By End User - Homecare, Hospital